

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Tuesday, April 11, 2017 3:14 PM  
**To:** Rizwana Sproule  
**Cc:** 'Alex Babayan'  
**Subject:** RE: BLA 125643/0 Rolling Submission: Site Selection Request for Information

**Importance:** High

Dear Dr. Sproule,

We have the following request for information:

To facilitate the selection of the clinical sites for inspection, submit as a dataset (1 site per row) the following information from the clinical trial ZUMA1. Submit this information as a SAS transport file, and include a define.pdf file.

Please respond by close of business Thursday, April 13, 2017.

- Site number
- Principal investigator
- Location: Address, City, State, Country
- Contact Information: Name, Phone, Fax, Email
- Number of subjects who signed informed consent
- Number of subjects who received leukapheresis
- Number of subjects who received KTE-C19
- Number of subjects who achieved CR or PR, per investigator
- Number of subjects who achieved CR or PR, per central review
- Number of subjects who achieved CR, per investigator
- Number of subjects who achieved CR, per central review
- Number of major protocol violations
- Number of deaths
- Number of subjects who experienced SAEs

Thank You

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax:301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not

authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."